Dapagliflozin- Cost-effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in Argentina and Chile
May 1, 2014, 00:00 AM
10.1016/j.jval.2014.03.1449
https://www.valueinhealthjournal.com/article/S1098-3015(14)01500-9/fulltext
Section Title :
Diabetes/Endocrine Disorders I
Section Order :
920
First Page :
A248
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01500-9&doi=10.1016/j.jval.2014.03.1449